Sodium nitrite inhalation - Mast Therapeutics

Drug Profile

Sodium nitrite inhalation - Mast Therapeutics

Alternative Names: AIR-001; Aironite

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator National Heart, Lung and Blood Institute
  • Developer Aires Pharmaceuticals; Mast Therapeutics; Mayo Clinic; University of Pittsburgh
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure; Pulmonary hypertension
  • Phase I/II Pseudomonal infections
  • Discontinued Pulmonary arterial hypertension

Most Recent Events

  • 06 Mar 2017 Aires Pharmaceuticals and University of Pittsburgh enter into an agreement for the phase I/II trial in Pseudomonal infections in Cystic fibrosis patients
  • 06 Mar 2017 Phase-I/II clinical trials in Pseudomonal infections in USA (Inhalation)
  • 28 Feb 2017 Phase-II development for Heart failure with preserved ejection fraction (HFpEF) and for Pulmonary hypertension secondary to HFpEF is ongoing in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top